MedTrace Logo

Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients

NCT02483637 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-02-23

No results posted yet for this study

Summary

This study evaluates the safety of RejuvenAir Cryospray therapy to treat symptomatic chronic bronchitis patients with airflow restrictions.

Conditions

  • Bronchitis, Chronic
  • Cryotherapy Effect

Interventions

DEVICE

RejuvenAir

Device: RejuvenAir

Sponsors & Collaborators

  • CSA Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Heather Nigro · CSA Medical

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2019-05-31
Completion
2022-05-20

Countries

  • Canada
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02483637 on ClinicalTrials.gov